South Korea’s Celltrion expects minimal impact from Trump’s drug pricing order
Seoul: Celltrion, a leading South Korean biopharmaceutical company, on Thursday said its business will remain largely unaffected by…
Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union
INCHEON, South Korea, December 15, 2024–(BUSINESS WIRE)–Celltrion today announced that the Committee for Medicinal Products for Human Use…